Nano Dimension's $890M AI Healthcare Pivot Hits a Boardroom Revolt

A 3D printing company wants out of 3D printing

Nano Dimension built its reputation on machines that print circuit boards and metal parts. The Israeli company's DragonFly and other inkjet additive systems turned up in labs that needed to prototype electronics without a factory. Now the company is trying to become something else entirely.

Last month Nano Dimension signed a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics firm. The proposed deal is valued at roughly $890 million. If it closes, a company known for 3D printers would pivot hard toward AI-driven healthcare.

The pivot was already shaky. Then the board exploded.

The term sheet is non-binding, which means there is no guarantee the merger happens. That uncertainty just got worse. A settlement announced on July 17 with activist shareholder Murchinson Ltd has reshaped the company from the top down.

Four directors resigned. Three Murchinson nominees joined the board. Chief Executive David Stehlin stepped down, making him the fourth CEO to leave the company in just 18 months. Nano Dimension named Moshe Rozenbaum as interim chief executive and cancelled a planned extraordinary shareholder meeting that had been set for July 31.

Why a printer maker is chasing healthcare

Nano Dimension has spent years pushing additive manufacturing into electronics and aerospace supply chains. Those markets are real but slow, and the company has struggled to show consistent profit. Preventive health and diagnostics, powered by AI, is a faster-growing story that investors have rewarded elsewhere.

The bet is that the data and software skills behind AI diagnostics transfer better to the balance sheet than another round of industrial printers. Whether shareholders who bought in for manufacturing want that trade is exactly the question Murchinson forced into the open.

What it means for the 3D printing sector

A founder-led additive company walking away from its own market would be a signal. It would tell the rest of the industry that the smarter money sees faster returns in AI-adjacent healthcare than in selling more machines.

For now the $890 million plan sits between a signed term sheet and a board that no longer looks like the one that signed it. Nano Dimension has until the deal's conditions are met to prove the pivot is more than a survival move. Given the churn at the top, that proof is not close yet.